anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Bilateral internal mammary artery (BIMA) in coronary artery bypass grafting (CABG) has been shown to provide long-term clinical benefits over single internal mammary artery (SIMA) grafting. Nevertheless, the perceived technical complexity of the procedure and concerns about potential early postoperative complications, particularly, sternal wound infections, have led to a utilization rate of BIMA grafting of less than 5% in the United States. We systematically compared early (30-day) postoperative outcomes between the BIMA and SIMA cohorts in patients with similar baseline characteristics. A retrospective single-center study was conducted on matched patients, using stabilized inverse probability treatment weighting to mitigate bias between the 2 study cohorts. From 546 patients who underwent off-pump CABG initially identified, we examined 328 BIMA and 213 SIMA grafts from the matched samples. Despite using 60.4% BIMA grafts, we observed similar rates of 30-day overall and cardiac mortality between the BIMA and SIMA groups. The rates of 30-day postoperative complications, including superficial and deep sternal wound infections, stroke, sepsis, acute kidney injury, and cardiac arrest, were similar between the 2 groups. The rates of 30-day overall and cardiac readmission were also similar. In addition, the median length of hospital stays, intensive care unit stay, and ventilation times were similar between the 2 groups. In conclusion, our data suggest that a BIMA utilization rate of 60.4% in off-pump CABG procedures is achievable without causing any significant increment in early postoperative complications, including deep sternal wound infection.
Extended error protected communication system. An extended consumer communication system uses a signal that is error protected by a block code. The generator polynomial isGn(x)=go(x) . . . gn(x)which is factorizable, and each of the factors implement a linear and systematic code. Generally, each of the factors adds redundancy and raises the level of error protection. In this way, redundancy that is associated to a later term of the sequence occupies code positions that are protected by at least one earlier term in the sequence and may in consequence be used for positioning data that is protected by such earlier term, upon surrender of such higher protection level.
Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
PURPOSE: A composition containing Rhamnus davurica Pall. Extract is provided to prevent and treat bone diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating bone diseases contains Rhamnus davurica Pall. extract as an active ingredient. The bone diseases include osteroporosis, osteromalacia, osteitis fibrosa, rachitis, or metabolic bone diseases. The extract is prepared from fruits and leaves of Rhamnus davurica Pall. A food composition for treating and relieving the bone diseases contains the extract as an active ingredient.
Sestrin2 (SESN2) is a stress-inducible protein and acts as a neuroprotective regulator. The present study aimed to explore the antidepressant activity of SESN2 and its relevant mechanism. Depression mouse model was established by chronic unpredictable mild stress (CUMS) for a successive 5 weeks. Behaviors tests were conducted to examine depressive-like behaviors including sugar preference test, tail suspension test and open field test. The expression of SESN2 and ferroptosis-related proteins was examined by western blot. The production of cytokines was measured by ELISA. Iron deposition was assessed using Prussian blue staining and Fe 2+ content was measured using commercial kits. Lipid peroxidation was evaluated by thiobarbituric acid reactive substances assay. BV-2 cells were treated with LPS to induce microglial activation, which was evaluated by the iba-1 level adopting immunofluorescence assay. The ferroptosis inducer Erastin was adopted for the pretreatment in BV-2 cells to conduct a rescue experiment. SESN2 was downregulated in CUMS-induced mice, and SESN2 overexpression dramatically ameliorated CUMS-induced depression-like behaviors. Meanwhile, SESN2 reduced the production of pro-inflammatory cytokines and iba-1 level in hippocampus of CUMS mice, as well as reducing iron deposition and lipid peroxidation, demonstrating that SESN2 reduced microglial activation, neuroinflammation and ferroptosis in CUMS mice. Similarly, SESN2 also restricted iba-1 level, pro-inflammatory cytokines production, and ferroptosis in LPS-induced BV-2 cells, which was partly reversed by additional treatment of Erastin. These findings suggest that SESN2 possesses potent antidepressant property through inhibiting ferroptosis and neuroinflammation.
The present invention relates to a hair-treatment fermentation composition which contains a fermented rice bran/soybean extract, has excellent effects of protecting the hair, waving the hair and retaining the waved hair style, and relieves an offensive smell originating in perming agents. In test performed on hair that has been treated with commercially available perming agents, by applying the hair-treatment composition of the present invention to the hair, the moisture content and the cysteic acid content of the hair are measured. As a result, the hair shows little change in the moisture content due to the change in the environmental humidity and capability of retaining moisture enhanced, as compared to a control group. Also, the composition shows an enhanced effect of inhibiting the formation of cysteic acid by hydrolyzed keratin. When the hair treatment composition in accordance with the present invention is used in perming, the hair is effectively waved and the waved hair style can be sustained. Moreover, the composition relieves the cold smell originating mainly in sulfur components in perming agents.
BACKGROUND: Prosthetic substitution of the talus presents a significant challenge to the foot and ankle surgeon. The shear and compressive forces on the talus and its tenuous blood supply lead to high rates of avascular necrosis and eventual talar collapse. The purpose of this systematic review is to evaluate whether total ankle total talus replacement (TATTR) leads to improved clinical and radiographic outcomes with appropriate safety metrics in patients with a history of avascular necrosis or significant trauma.
METHODS: We searched the concepts of talus, prosthesis, and arthroplasty in MEDLINE (PubMed), Embase (Elsevier), CINAHL Complete (EBSCOhost), and Scopus (Elsevier) from the database's inception through March 9, 2023. Inclusion Criteria were 1) previous trauma to the talus, 2) post-traumatic arthritis to the tibiotalar joint, 3) avascular necrosis of talus, 4) multiple failed prior interventions, 5) degenerative osteoarthritis to the tibiotalar joint, and 6) inflammatory arthropathy to tibiotalar joint. Patients less than 18 years of age and manuscripts in non-English languages were excluded.
RESULTS: Of the 7625 references, 16 studies met the inclusion criteria, yielding data from 136 patients (139 ankles). The studies varied in design, with case reports and retrospective case series being predominant. The overall weighted average modified Coleman Methodology Score (mCMS) was 70.4 out of 100, indicating moderate flaws in study design that may be subject to various forms of bias and possible confounders. Demographics showed a diverse range of etiologies, with alumina ceramic being the primary prosthesis material. Functional scores demonstrated improvements in dorsiflexion and plantarflexion, although patient-reported outcome measures (PROs) were inconsistently reported. Complications included fractures, heterotopic ossification, prolonged wound healing, and infections. Revision details were sparsely reported.
CONCLUSION: TATTR is a promising treatment modality for improving short-term functional outcomes for patients with avascular necrosis or trauma-related issues. However, this systematic review underscores the need for standardized reporting, longer-term follow-ups, and further research to establish the procedure's efficacy and safety, particularly in comparison to other treatment modalities.
LEVEL OF EVIDENCE: III, Systematic Review of Level IV Studies.
The present disclosure includes digitizing user symptoms. A processor may receive user provided data from one or more data collection devices. A processor may access a historical database. The historical database may include historical user provided data. A processor may generate a user data packet based, at least in part on, the user provided data and the historical database. A processor may display the user data packet to one or more authorized user and one or more other correlating information.
A urinary balloon catheter will be placed through the cervix into the lower uterine segment and the bulb inflated with 40ml of saline. The catheter will be taped to the patient's thigh and placed under traction using a liter bag of saline. The catheter will be deflated and removed after 6 hours. If spontaneously expelled from the uterus, time of expulsion will be noted. Six hours after insertion of catheter, a digital exam will be performed and Bishop score recorded. If no active labor at time of catheter removal or expulsion, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
DUETACT tablets are a thiazolidinedione and a sulfonylurea combination product that contains two oral antihyperglycemic agents: pioglitazone and glimepiride. The concomitant use of pioglitazone and a sulfonylurea, the class of drugs that includes glimepiride, has been previously approved based on clinical trials in patients with type 2 diabetes inadequately controlled on a sulfonylurea. Additional efficacy and safety information about pioglitazone and glimepiride monotherapies may be found in the prescribing information for each individual drug.

Pioglitazone is an oral antidiabetic medication.

Pioglitazone [(±)-5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-] thiazolidinedione monohydrochloride contains one asymmetric carbon, and the compound is synthesized and used as the racemic mixture. The two enantiomers of pioglitazone interconvert in vivo. No differences were found in the pharmacologic activity between the two enantiomers. The structural formula is as shown:

Pioglitazone hydrochloride is an odorless, white crystalline powder that has a molecular formula of C19H20N2O3S•HCl and a molecular weight of 392.90 daltons. It is soluble in N,N‑dimethylformamide, slightly soluble in anhydrous ethanol, very slightly soluble in acetone and acetonitrile, practically insoluble in water, and insoluble in ether.

Glimepiride is an oral sulfonylurea chemically identified as 1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)-urea (C24H34N4O5S) with a molecular weight of 490.62. Glimepiride is a white to yellowish-white, crystalline, odorless to practically odorless powder and is practically insoluble in water. The structural formula is:

DUETACT is available as a tablet for oral administration containing 30 mg pioglitazone (as the base) with 2 mg glimepiride (30 mg/2 mg) or 30 mg pioglitazone (as the base) with 4 mg glimepiride (30 mg/4 mg) formulated with the following excipients: croscarmellose sodium NF, lactose monohydrate NF, magnesium stearate NF, hydroxypropyl cellulose NF, polysorbate 80 NF, and microcrystalline cellulose NF.
This editorial discusses a recently published paper in the World Journal of Gastroenterology. Our research focuses on p53's regulatory mechanism for controlling ferroptosis, as well as the intricate connection between ferroptosis and liver diseases. Ferroptosis is a specific form of programmed cell death that is de-pendent on iron and displays unique features in terms of morphology, biology, and genetics, distinguishing it from other forms of cell death. Ferroptosis can affect the liver, which is a crucial organ responsible for iron storage and meta-bolism. Mounting evidence indicates a robust correlation between ferroptosis and the advancement of liver disorders. P53 has a dual effect on ferroptosis through various distinct signaling pathways. However, additional investigations are required to clarify the regulatory function of p53 metabolic targets in this complex association with ferroptosis. In the future, researchers should clarify the mechanisms by which ferroptosis and other forms of programmed cell death contribute to the progression of liver diseases. Identifying and controlling important regulatory factors associated with ferroptosis present a promising therapeutic strategy for liver disorders.
Subjects will be randomly assigned to treatment using a permuted-block randomization algorithm. Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children \>=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to \<2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
Diabetes remains a common leading cause of morbidity and mortality among population worldwide over decades. Obesity, a crucial risk factors for developing T2DM, commonly exists with insulin resistance and impaired beta-cell function. Early management in individuals at high risk of T2DM should be therefore considered for preventing or delaying the progression of diabetes and diabetic complications.

Since 1-deoxynojirimycin (DNJ), the major antihyperglycemic compound of mulberry leaves, inhibits alpha-glucosidase activities, ingestion of mulberry leaves results in the suppression of postprandial hyperglycemia. Long-term effects of mulberry leaves on glycemic profiles have been demonstrated in numerous clinical studies; however, the results were controversial. In addition, no study was conducted in patients with obesity. As a result, this open-label, randomized controlled study aims to investigate efficacy and safety of mulberry leaves in combination with lifestyle intervention (diet control) on glycemic control in non-diabetic patients with obesity and patients with early-stage T2DM. Efficacy of the interventions will be assessed based on the changes in glycemic indexes, expression of proteins related to insulin resistance and T2DM, and lipid profiles. Meanwhile, safety will be measured by the changes in renal and hepatic enzymes and patient-self reports. The outcomes will be monitored at 4-week interval throughout 12 weeks of the study period.
BACKGROUND: Sarcopenia is frequently found in patients with heart failure with reduced ejection fraction (HFrEF) and is associated with reduced exercise capacity, poor quality of life and adverse outcomes. Recent evidence suggests that axial thoracic skeletal muscle size could be used as a surrogate to assess sarcopenia in HFrEF. Since diabetes mellitus (DM) is one of the most common comorbidities with HFrEF, we aimed to explore the potential association of axial thoracic skeletal muscle size with left ventricular (LV) remodeling and determine its prognostic significance in this condition.
METHODS: A total of 243 diabetes patients with HFrEF were included in this study. Bilateral axial thoracic skeletal muscle size was obtained using cardiac MRI. Patients were stratified by the tertiles of axial thoracic skeletal muscle index (SMI). LV structural and functional indices, as well as amino-terminal pro-B-type natriuretic peptide (NT-proBNP), were measured. The determinants of elevated NT-proBNP were assessed using linear regression analysis. The associations between thoracic SMI and clinical outcomes were assessed using a multivariable Cox proportional hazards model.
RESULTS: Patients in the lowest tertile of thoracic SMI displayed a deterioration in LV systolic strain in three components, together with an increase in LV mass and a heavier burden of myocardial fibrosis (all P < 0.05). Moreover, thoracic SMI (β = -0.25; P < 0.001), rather than body mass index (β = -0.04; P = 0.55), was independently associated with the level of NT-proBNP. The median follow-up duration was 33.6 months (IQR, 20.4-52.8 months). Patients with adverse outcomes showed a lower thoracic SMI (40.1 [34.3, 47.9] cm2/m2 vs. 45.3 [37.3, 55.0] cm2/m2; P < 0.05) but a similar BMI (P = 0.76) compared with those without adverse outcomes. A higher thoracic SMI indicated a lower risk of adverse outcomes (hazard ratio: 0.96; 95% confidence interval: 0.92-0.99; P = 0.01).
CONCLUSIONS: With respect to diabetes patients with HFrEF, thoracic SMI is a novel alternative for evaluating muscle wasting in sarcopenia that can be obtained by a readily available routine cardiac MRI protocol. A reduction in thoracic skeletal muscle size predicts poor outcomes in the context of DM with HFrEF.
The invention relates to a method for diagnosing impaired hair growth or for determining the probability of impaired hair growth (predisposition) in mammalians. According to the invention, the expression of at least two cyclically expressed genes in a sample is analyzed and (a) one of the two genes has the maximum expression peak during the anagen phase while (b) the second gene has the maximum expression peak during the catagen phase or during the telogen phase. The invention further relates to a method for diagnosing the effectiveness of the treatment of impaired hair growth in mammalians, according to which the expression of at least two cyclically expressed genes in a sample is analyzed and (a) one of the two genes has the maximum expression peak during the anagen phase while (b) the second gene has the maximum expression peak during the catagen phase or during the telogen phase. Preferably, the expression of further genes with a cyclic expression curve is analyzed according to the inventive method. The invention also relates to a method for isolating inhibitors of impaired hair growth and for improving such inhibitors. Finally, the invention relates to methods for producing drugs or medicinal products in which the identified or improved inhibitor is formulated together with a pharmaceutically acceptable excipient or diluent.
Participants in the morning bright light + afternoon bright light (MBL+ ABL) group will receive bright light from 2 light boxes on 3 consecutive days in the laboratory. The morning exposure will be 1.5 h and the afternoon exposure will be 1.5 h. Bright light exposures will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier ("phase advance").
Adult patients (≥18 years of age) with CKD were identified in Alberta during the case ascertainment period (April 1, 2010, to March 31, 2019), based on a validated algorithm incorporating ICD-9-CM/ICD-10-CA coding, estimated glomerular filtration rate, and albuminuria laboratory tests. This is a non-interventional, observational study, and thus, no intervention was administered.
Methods are disclosed to enhance controlled localization and/or release of an agent at an anatomical and/or physiological site where the agent is desirable. In one embodiment, the method localizes vector transfected with a gene(s) that enhances neovascularization (i.e., genes encoding angiogenic agents). In another embodiment, the method localizes genes that inhibit neovascularization (i.e., genes encoding antiangiogenic agents) at sites where new blood vessel growth is undesirable. The vector is provided in a biocompatible substance substantially preventing migration of the vector from the site in need of therapy. The substance may be a matrix, gel, a polymer, liposome, capsule, nanoparticle, microparticle. The substance may form in situ, for example, a fibrin entraining mesh or network form from fibrinogen and thrombin.
A method and system of collecting, organizing, and accessing medical data and records via a biometric read and scan. The system involves the implementation of a mechanism by which an individual's biometric signature is linked to his or her medical data, which is stored digitally and is accessible worldwide via a could-based database. The provided system is configured to be used in real-time, especially during emergency situations, to assist an individual who is not responding, and is in critical condition. The system includes multiple components, including a biometric reader/scanner device, a secured relational database which provides semantically categorized medical emergency content, a mobile device application, and applicable data encryption and security protocols. The mobile device application serves as a conduit for the user to contact the services of 911 instantly, as well as provide a service to the medical records of the user. The system includes a medical card.
The invention discloses a medicine for treating herpes and applications of the medicine in treating herpes. The medicine is prepared from the following components in percentage by weight: 1%-5% of polyving akohol, 1%-5% of gum rosin, 1%-5% of beewax, 1%-30% of gum turpentine, 1%-18% of purified water, and the balance of alcohol or/and methanol. The medicine also contains the following components: sophocarpidine, oxymatrine, herba cirsii japonici, borneol, glycerol, a transdermal enhancer and a film-forming material. The invention provides the medicine for treating herpes and the applications of the medicine in treating herpes. The medicine can well treat and prevent herpes, so that the pain of patients can be alleviated. A layer of film is formed after the medicine is applied to the herpes, so that viruses and oxygen in air can be isolated, the regrowth of the herpes can be prevented, and the herpes treating speed can be accelerated.
Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.
Group 2 consists of metastatic breast cancer patients. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires at one time point only.
FIELD: organic chemistry, chemical technology. SUBSTANCE: invention relates to novel method of synthesis of halogen-o-hydroxydiphenyl compounds of the formula (1)   where X means +O- or -CH 2 -; m = from 1 to 3; n = 1 or 2 which are used for protection of organic materials from microorganisms and to novel acyl compounds of the formula (8)   that are intermediate substances where R means unsubstituted C 1 -C 8 -alkyl or substituted with 1-3 halogen atoms or hydroxy-group; or unsubstituted C 6 -C 12 -aryl or C 6 -C 12 -aryl substituted with 1-3 halogen atoms, C 1 -C 5 -alkyl or C 1 -C 8 -alkoxy-group. Method of synthesis of compounds of the formula (1) involves four stages. On the first stage corresponding diphenyl compound of the formula (4)   is chlorinated with gaseous chlorine mainly and in the presence of propyl sulfide and the equimolar amount of aluminium chloride preferably. On the second stage synthesized corresponding chlorinated compound of the formula (5)   is acylated with acetyl chloride mainly by Friedel-Crafts reaction in the presence of Lewis acid, for example, aluminium chloride in the equimolar ratio of acetyl chloride and aluminium chloride usually in the presence of halogenated solvent with the following possible chlorination of synthesized product after acylation. It is possible to carry out acylation and possible chlorination reactions in a single reactor. On the third stage synthesized acyl compound of the formula (6)   where values of substitute R are indicated above is oxidized with as a rule with mixture of maleic anhydride, complex urea-hydrogen peroxide and acetic acid as solvent. On the fourth stage synthesized oxidized compound of the formula (7)   where values of substitute R are indicated above is hydrolyzed. Method ensures to inhibit undesirable by-side reactions. EFFECT: improved method and efficiency of method. 15 cl, 8 tbl